PE20231107A1 - Preparacion y almacenamiento de formulaciones de rna liposomal adecuadas para terapia - Google Patents

Preparacion y almacenamiento de formulaciones de rna liposomal adecuadas para terapia

Info

Publication number
PE20231107A1
PE20231107A1 PE2023001330A PE2023001330A PE20231107A1 PE 20231107 A1 PE20231107 A1 PE 20231107A1 PE 2023001330 A PE2023001330 A PE 2023001330A PE 2023001330 A PE2023001330 A PE 2023001330A PE 20231107 A1 PE20231107 A1 PE 20231107A1
Authority
PE
Peru
Prior art keywords
therapy
preparation
storage
composition
formulations suitable
Prior art date
Application number
PE2023001330A
Other languages
English (en)
Inventor
Heinrich Haas
Sebastian Horner
Thomas Michael Hiller
Tobias Kind
Tijana Bacic
Original Assignee
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNTech SE filed Critical BioNTech SE
Publication of PE20231107A1 publication Critical patent/PE20231107A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE PARTICULAS DE LIPOPLEXO DE RNA QUE COMPRENDEN A) RNA; B) AL MENOS UN LIPIDO CATIONICO TAL COMO 1,2-DI-O-OCTADECENIL-3-TRIMETILAMONIO PROPANO (DOTMA); C) AL MENOS UN LIPIDO ADICIONAL TAL COMO 1,2-DI-(9Z-OCTADECENOIL)-SN-GLICERO-3-FOSFOETANOLAMINA (DOPE); D) CLORURO DE SODIO A UNA CONCENTRACION DE 10 mM O MENOS; E) UN ESTABILIZADOR TAL COMO SACAROSA O TREHALOSA A UNA CONCENTRACION ENTRE EL 10% Y EL 15% EN PESO POR PORCENTAJE DE VOLUMEN (% P/V); Y F) UN TAMPON TAL COMO ACIDO 2-[4-(2-HIDROXIETIL)PIPERAZIN-1-IL]ETANOSULFONICO (HEPES); DONDE LA COMPOSICION TIENE UN PH DE 6,0 A 7,5. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES EN LAS QUE LA PROVISION DE UN PEPTIDO O PROTEINA A UN SUJETO DA COMO RESULTADO UN EFECTO TERAPEUTICO O PROFILACTICO.
PE2023001330A 2020-10-01 2021-09-30 Preparacion y almacenamiento de formulaciones de rna liposomal adecuadas para terapia PE20231107A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2020077578 2020-10-01
PCT/EP2021/076947 WO2022069632A1 (en) 2020-10-01 2021-09-30 Preparation and storage of liposomal rna formulations suitable for therapy

Publications (1)

Publication Number Publication Date
PE20231107A1 true PE20231107A1 (es) 2023-07-19

Family

ID=77999005

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023001330A PE20231107A1 (es) 2020-10-01 2021-09-30 Preparacion y almacenamiento de formulaciones de rna liposomal adecuadas para terapia

Country Status (14)

Country Link
US (1) US20240269321A1 (es)
EP (1) EP4221680A1 (es)
JP (1) JP2023544343A (es)
KR (1) KR20230079064A (es)
CN (1) CN116194081A (es)
AR (1) AR123677A1 (es)
AU (1) AU2021351887A1 (es)
CA (1) CA3193985A1 (es)
CR (1) CR20230147A (es)
IL (1) IL300681A (es)
MX (1) MX2023003695A (es)
PE (1) PE20231107A1 (es)
TW (1) TW202228727A (es)
WO (1) WO2022069632A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024160828A1 (en) * 2023-01-31 2024-08-08 BioNTech SE Compositions and methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110159023A1 (en) 2008-08-25 2011-06-30 Solomon Langermann Pd-1 antagonists and methods for treating infectious disease
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
US20110319473A1 (en) * 2010-06-29 2011-12-29 Surmodics, Inc. Compositions and methods for enhancement of nucleic acid delivery
JP2021500324A (ja) * 2017-10-20 2021-01-07 バイオエヌテック エールエヌアー ファーマシューティカルズ ゲーエムベーハーＢｉｏｎｔｅｃｈ Ｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｇｍｂｈ 治療に適するリポソームｒｎａ製剤の調製および保管
WO2020200472A1 (en) * 2019-04-05 2020-10-08 Biontech Rna Pharmaceuticals Gmbh Preparation and storage of liposomal rna formulations suitable for therapy

Also Published As

Publication number Publication date
US20240269321A1 (en) 2024-08-15
CR20230147A (es) 2023-08-18
MX2023003695A (es) 2023-04-21
IL300681A (en) 2023-04-01
KR20230079064A (ko) 2023-06-05
CN116194081A (zh) 2023-05-30
CA3193985A1 (en) 2022-04-07
EP4221680A1 (en) 2023-08-09
JP2023544343A (ja) 2023-10-23
AU2021351887A1 (en) 2023-03-16
TW202228727A (zh) 2022-08-01
AR123677A1 (es) 2023-01-04
WO2022069632A1 (en) 2022-04-07

Similar Documents

Publication Publication Date Title
Clunes et al. Cystic fibrosis: the mechanisms of pathogenesis of an inherited lung disorder
US8153162B2 (en) Purified amniotic membrane compositions and methods of use
MX2019011004A (es) Compuestos y composiciones para la administracion intracelular de agentes terapeuticos.
PE20131324A1 (es) Formulacion subcutanea de anticuerpo anti-her2
ES2599034T3 (es) Alfa-1-microglobulina para su uso en el tratamiento de enfermedades relacionadas con mitocondrias
PE20140797A1 (es) COMPOSICIONES Y METODOS PARA ADMINISTRACION DE ARNm
PE20130579A1 (es) Composiciones y metodos para suministro al sistema nervioso central de iduronato-2-sulfatasa
ECSP066327A (es) Composición de fexofenadina y proceso para prepararla
AR108631A1 (es) Formulación de neurotoxinas
BR112014026162A2 (pt) Proteína de fusão ou variante da mesma, molécula de ácido nucleico, vetor de expressão, célula hospedeira, animal não humano geneticamente modificado, planta geneticamente modificada, agente terapêutico para doenças melhoradas por lactoferrina, composição farmacêutica, e, método para preparar a proteína de fusão ou variante da mesma
PE20231107A1 (es) Preparacion y almacenamiento de formulaciones de rna liposomal adecuadas para terapia
BR112021019520A2 (pt) Composição farmacêutica, método para tratar a síndrome de hunter e uso de uma composição farmacêutica
US8758730B2 (en) Compositions, use and method for the use of surface active proteins in topical drug delivery across keratin
RU2573943C2 (ru) Применение prdx2 и/или prdx6 для получения фармацевтической композиции для лечения или предотвращения повреждения, старения или заболевания, вызванных повышением уровня активных форм кислорода
BR112015019568A2 (pt) Peptídeo isolado, composição compreendendo o mesmo e uso do mesmo
ES2740273T3 (es) Péptidos antimicrobianos
Fu et al. Combination of lithium chloride and pEGFP-N1-Bm K CT effectively decreases proliferation and migration of C6 glioma cells
CA2928526A1 (en) Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
JP2018521129A (ja) タンパク質の安定化のための方法および組成物
US10858395B2 (en) Skin-penetrating peptide and method for using same
WO2014144017A2 (en) Compositions and methods for treating conditions that affect epidermis
RU2695132C1 (ru) Фармацевтическая композиция для улучшения реологических свойств мокроты на основе фермента нуклеазы Serratia marcescens
Salehi et al. Absorption enhancer approach for protein delivery by various routes of administration: A rapid review
WO2021125291A1 (ja) グルタチオン配合組成物
ALBERTO-SILVA et al. Molecular and cellular mechanisms of neuroprotection by oligopeptides from snake venoms.